Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

This study is a single-center, open, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or plasma cell leukemia.

flow cytometry
measurable disease
ejection fraction
multiple myeloma
refractory multiple myeloma
  • 0 views
  • 05 Jun, 2022
  • 1 location
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

cell leukemia that has come back or does not respond to treatment. High throughput screen tests many different drugs that kill multiple myeloma cells in individual chambers at the same time. Matching a

measurable disease
multiple myeloma
serum protein
monoclonal antibody therapy
bone marrow procedure
  • 27 views
  • 11 May, 2022
  • 1 location
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. …

cyclophosphamide
lymphocyte immune globulin
blood cell count
graft versus host disease
chronic myeloid leukemia
  • 64 views
  • 24 Oct, 2022
  • 1 location
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).

hematologic disorder
hypodiploidy
preparative regimen
blast cells
cyclophosphamide
  • 146 views
  • 25 Feb, 2022
  • 1 location
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.

cytopenia
cyclophosphamide
graft versus host disease
chronic myeloid leukemia
blast crisis
  • 102 views
  • 24 Feb, 2022
  • 1 location
Allo HSCT Using RIC for Hematological Diseases

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus …

hematologic disorder
cytopenia
hypodiploidy
raeb i
renal impairment
  • 27 views
  • 24 Feb, 2022
  • 1 location
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate …

preparative regimen
cyclophosphamide
graft versus host disease
chronic myeloid leukemia
blood cell count
  • 58 views
  • 06 May, 2022
  • 1 location
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients. The only potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed …

measurable disease
graft versus host disease
lenalidomide
melphalan
bortezomib
  • 65 views
  • 15 Mar, 2022
  • 1 location
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

progressive disease
refractory multiple myeloma
aspirin
immunoglobulins
monoclonal protein
  • 36 views
  • 29 Apr, 2022
  • 8 locations
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry (CARE-Heme)

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information …

  • 0 views
  • 16 Oct, 2022